Compound · clinical trials

Trastuzumab Rezetecan clinical trials

Also listed in trial records as SHR-A1811, T-DXh, SHR-A1811 group

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 75 trials in our China register that name Trastuzumab Rezetecan as an intervention. Synced 10 Nov 2026

75Current trials

42Recruiting now

26Lead sponsors

1Country register

Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Synced 10 Nov 2026 · Editorial standards

At a glance

Trastuzumab Rezetecan is named as an intervention in 75 current clinical trials in our China register. 42 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Jiangsu HengRui Medicine Co., Ltd (14). The most-studied condition is Breast Cancer.

How Trastuzumab Rezetecan works

All drug targets →

Diseases it has been tested for in clinical trials, by furthest phase

Breast cancerPhase 3
Colorectal cancerPhase 3
Fallopian tube cancerPhase 3
Gastric adenocarcinomaPhase 3
Gastric cancerPhase 3
Gastroesophageal junction adenocarcinomaPhase 3
Malignant epithelial tumor of ovaryPhase 3
Non-small cell lung carcinomaPhase 3
Ovarian carcinomaPhase 3
Primary peritoneal carcinomaPhase 3

20 diseases in all

Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL5314712, CC BY-SA 3.0. The Guide to Pharmacology has no record of this medicine, so its targets rest on ChEMBL alone. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.

Patient leaflets for Trastuzumab Rezetecan

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

UK
United Kingdom: Search MHRA Products
Patient information leaflets and SmPCs for UK-licensed products.
US
United States: Search DailyMed
FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Trials by status

Recruiting4256%
Not yet open2331%
Active, closed1013%

Trials by phase

Phase 24864%
Phase 31723%
Phase 1/279%
Phase 111%
Observational11%
Phase 411%

Clinical trials of Trastuzumab Rezetecan

75 trials

Study	Phase	Status	Lead sponsor	Registers
Real-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast Cancer NCT07600164 · ClinicalTrials.gov ↗ · HER2 + Breast Cancer, Advanced Breast Cancer	Phase 4	Recruiting	Peking University People's Hospital	China
SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen NCT06123494 · ClinicalTrials.gov ↗ · HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma	Phase 3	Recruiting	Jiangsu HengRui Medicine Co., Ltd	China
A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations NCT06430437 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer With HER2- Mutations	Phase 3	Recruiting	Jiangsu HengRui Medicine Co., Ltd	China
A Study of SHR-A1811 in Subjects With Ovarian Cancer NCT06828354 · ClinicalTrials.gov ↗ · Ovarian Cancer	Phase 3	Recruiting	Jiangsu HengRui Medicine Co., Ltd	China
A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer NCT07111832 · ClinicalTrials.gov ↗ · PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer	Phase 3	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd	China
A Phase III Study of SHR-A1811 in Combination With Chemotherapy and Adebrelimab in Previously Untreated Patients With Gastric or Gastroesophageal Junction Adenocarcinoma NCT07118527 · ClinicalTrials.gov ↗ · Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma	Phase 3	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd	China
Artificial Intelligence Model-Guided Neoadjuvant Anti-HER2 Targeted Therapy NCT07528716 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 3	Recruiting	Fudan University	China
A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer NCT07679360 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer	Phase 3	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd	China
Reverse Triple Negative Immune Resistant Breast Cancer NCT05076682 · ClinicalTrials.gov ↗ · Triple-negative Breast Cancer	Phase 2	Recruiting	Fudan University	China
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy NCT05582499 · ClinicalTrials.gov ↗ · Breast Neoplasm, Breast Cancer, Breast Tumors	Phase 2	Recruiting	Fudan University	China
SNF Platform Study of HR+/ HER2-advanced Breast Cancer NCT05594095 · ClinicalTrials.gov ↗ · Breast Neoplasm, Breast Cancer, Hormone Receptor Positive Tumor	Phase 2	Recruiting	Fudan University	China
A Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients NCT05635487 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer	Phase 2	Recruiting	Shengjing Hospital	China
Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases NCT05769010 · ClinicalTrials.gov ↗ · Metastatic Breast Cancer	Phase 2	Recruiting	Henan Cancer Hospital	China
A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer NCT05911958 · ClinicalTrials.gov ↗ · HER2 Low Breast Carcinoma	Phase 2	Recruiting	Henan Cancer Hospital	China
SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in HR Positive/HER2 Low Breast Cancer NCT06340230 · ClinicalTrials.gov ↗ · HR Positive/HER2 Low Breast Cancer	Phase 2	Recruiting	Shengjing Hospital	China
Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer NCT06433609 · ClinicalTrials.gov ↗ · Advanced Breast Cancer	Phase 2	Recruiting	Beijing GoBroad Hospital	China
Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer NCT06547736 · ClinicalTrials.gov ↗ · Pancreatic Cancer	Phase 2	Recruiting	Fudan University	China
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer NCT06649331 · ClinicalTrials.gov ↗ · Advanced Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer (TNBC)	Phase 2	Recruiting	Fudan University	China
A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer NCT06778031 · ClinicalTrials.gov ↗ · HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer	Phase 2	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd	China
SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC NCT06927180 · ClinicalTrials.gov ↗ · Breast Cancer Early Stage Breast Cancer (Stage 1-3)	Phase 2	Recruiting	Henan Cancer Hospital	China
Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast Cancer NCT07037199 · ClinicalTrials.gov ↗ · Advanced Breast Cancer	Phase 2	Recruiting	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer NCT07051486 · ClinicalTrials.gov ↗ · Recurrent or Metastatic Cervical Cancer	Phase 2	Recruiting	Jiangsu HengRui Medicine Co., Ltd	China
Trastuzumab Rezetecan Combined With Radiotherapy Versus Trastuzumab Rezetecan in the Treatment of HER2-positive Advanced Breast Cancer With Brain Metastases NCT07100600 · ClinicalTrials.gov ↗ · HER2-positive Advanced Breast Cancer, Brain Metastases, Radiotherapy	Phase 2	Recruiting	Henan Cancer Hospital	China
Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma NCT07102901 · ClinicalTrials.gov ↗ · Advanced Gastric Cancer, Metastatic Gastric Cancer, Gastroesophageal Junction Adenocarcinoma	Phase 2	Recruiting	Jiangsu HengRui Medicine Co., Ltd	China
A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer NCT07110571 · ClinicalTrials.gov ↗ · Gastric Cancer, Gastroesophageal-junction Cancer	Phase 2	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd	China
The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis NCT07203729 · ClinicalTrials.gov ↗ · HER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis	Phase 2	Recruiting	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) NCT07241793 · ClinicalTrials.gov ↗ · Urothelial Carcinoma, Advanced Urothelial Carcinoma, Urothelial Carcinoma Recurrent	Phase 2	Recruiting	Sun Yat-sen University	China
Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies NCT07309770 · ClinicalTrials.gov ↗ · Urachal Cancer, Advanced Solid Tumor Cancer, Antibody-drug Conjugates	Phase 2	Recruiting	Sheng Zhang	China
Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer NCT07340398 · ClinicalTrials.gov ↗ · HER2-positive Early Breast Cancer	Phase 2	Recruiting	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer NCT07497386 · ClinicalTrials.gov ↗ · Unresectable Locally Recurrent Breast Cancer, Unresectable Locally Metastatic Breast Cancer	Phase 2	Recruiting	Jiangsu HengRui Medicine Co., Ltd	China
Trastuzumab Rezetecan Neoadjuvant Therapy in THP-Insensitive HER2-Positive Early Breast Cancer NCT07647263 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer	Phase 2	Recruiting	The First Affiliated Hospital of Soochow University	China
Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract Cancer NCT07670273 · ClinicalTrials.gov ↗ · Biliary Tract Neoplasms Immunotherapy	Phase 2	Recruiting	Peking Union Medical College Hospital	China
Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract Cancer NCT07704177 · ClinicalTrials.gov ↗ · Biliary Tract Neoplasms Immunotherapy	Phase 2	Recruiting	Peking Union Medical College Hospital	China
Neoadjuvant Gemcitabine Plus Trastuzumab Rezetecan in HER2-positive UTUC NCT07741448 · ClinicalTrials.gov ↗ · UTUC	Phase 2	Recruiting	Zhiquan Hu	China
Phase II Study of SHR-A1811 for Ultra-Low HER2 Advanced Breast Cancer NCT07817082 · ClinicalTrials.gov ↗ · Advanced Breast Cancer With Ultra-Low HER2 Expression	Phase 2	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors. NCT06015048 · ClinicalTrials.gov ↗ · HER2-expressing Advanced Solid Tumors	Phase 1/2	Recruiting	Jiangsu HengRui Medicine Co., Ltd	China
Study of SHR-A1811 Combined With Pyrotinib and Bevacizumab in Advanced Breast Cancer With Brain Metastasis NCT06718933 · ClinicalTrials.gov ↗ · Breast Cancer Metastatic, Breast Cancer Brain Metastases	Phase 1/2	Recruiting	Fudan University	China
A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer NCT06840002 · ClinicalTrials.gov ↗ · Ovarian Cancer	Phase 1/2	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd	China
SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer NCT06859775 · ClinicalTrials.gov ↗ · Recurrent or Metastatic Cervical Cancer	Phase 1/2	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd	China
A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor NCT07140393 · ClinicalTrials.gov ↗ · Solid Tumor	Phase 1/2	Recruiting	Jiangsu HengRui Medicine Co., Ltd	China
A Study of SHR-4610 Injection in Patients With Advanced Solid Tumors NCT07231211 · ClinicalTrials.gov ↗ · Solid Tumors	Phase 1/2	Recruiting	Shanghai Shengdi Pharmaceutical Co., Ltd	China
A Clinical Study of SHR-A1811(sc) Subcutaneous Injection in Patients With Solid Tumor NCT07275242 · ClinicalTrials.gov ↗ · Solid Tumor	Phase 1	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd	China
SHR - A1811 Versus Chemotherapy for Platinum-resistant Recurrent Epithelial Ovarian Cancer NCT06990503 · ClinicalTrials.gov ↗ · Ovarian Cancer	Phase 3	Not yet open	Tongji Hospital	China
Famitinib Combined With SHR-A1811, Versus SHR-A1811 for CDK4/6 Inhibitors-resistent Advanced HR+/HER2- Breast Cancer With SNF4 Subtype NCT07382687 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 3	Not yet open	Fudan University	China
Trastuzumab Rezetecan Followed by Pyrotinib, Fulvestrant, and Dalpiciclib in HR-Positive, HER2-Positive Advanced Breast Cancer NCT07892274 · ClinicalTrials.gov ↗ · Metastatic Breast Cancer (MBC), HER2-Positive Breast Cancer, Hormone Receptor-Positive Breast Cancer	Phase 3	Not yet open	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung Cancer NCT07896005 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer	Phase 3	Not yet open	Suzhou Suncadia Biopharmaceuticals Co., Ltd	China
SHR-1811 Combined With Carboplatin in the Treatment of Advanced Breast Cancer With HER2 Expression NCT07047443 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Not yet open	Anhui Provincial Cancer Hospital	China
Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study NCT07179939 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer	Phase 2	Not yet open	Fudan University	China
Chemotherapy With or Without Adebrelimab and T-DXh as Neoadjuvant Therapy for HR+/HER2 Low Early Stage Breast Cancer NCT07317778 · ClinicalTrials.gov ↗ · Breast Cancer Early Stage Breast Cancer (Stage 1-3), HR Positive/HER2 Low Breast Cancer	Phase 2	Not yet open	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer NCT07466303 · ClinicalTrials.gov ↗ · Breast Cancer, Serplulimab Combined With SHR-A1811 as Neoadjuvant Therapy for Triple-Negative Breast Cancer	Phase 2	Not yet open	Xijing Hospital	China
Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver Metastases NCT07466927 · ClinicalTrials.gov ↗ · HER2-negative Breast Cancer	Phase 2	Not yet open	Fudan University	China
Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study. NCT07528898 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Not yet open	Hebei Medical University Fourth Hospital	China
Exploratory Study of SHR-A1811 Via Different Administration Routes in Patients NCT07560475 · ClinicalTrials.gov ↗ · HER2positive, Advanced Breast Cancer, HER2 + Breast Cancer	Phase 2	Not yet open	Tianjin Medical University Cancer Institute and Hospital	China
Trastuzumab Rezetecan(SHR-A1811) Combined With Ivonescimab (AK112) in Locally Advanced or Metastatic Non-small Cell Lung Cancer Harboring HER2 Gene Abnormalities NCT07630077 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer	Phase 2	Not yet open	Sun Yat-sen University	China
Efficacy and Safety of Trastuzumab Rezetecan or Trastuzumab Deruxtecan in Advanced Breast Cancer NCT07630103 · ClinicalTrials.gov ↗ · Advanced Breast Cancer	Phase 2	Not yet open	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
Trastuzumab Rezetecan Followed by Pyrotinib, and Trastuzumab Combined With Capecitabine as First-line Treatment for Advanced HER2-positive Breast Cancer NCT07766772 · ClinicalTrials.gov ↗ · HER2 + Breast Cancer, Advanced Breast Cancer	Phase 2	Not yet open	Fujian Cancer Hospital	China
Trastuzumab Rezetecan and Carboplatin ± Bevacizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-sensitive Recurrent Ovarian Cancer NCT07776171 · ClinicalTrials.gov ↗ · Ovarian Cancer, Platinum Sensitive Ovarian Cancer (PSOC)	Phase 2	Not yet open	Sun Yat-sen University	China
SHR-A1811 Monotherapy or Sequential THPy as Neoadjuvant Therapy for Stage II-III HER2-Positive Breast Cancer NCT07787338 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer	Phase 2	Not yet open	First Affiliated Hospital of Zhejiang University	China
Phase II Study of Trastuzumab Rezetecan Combined With Retlirafusp Alfa With or Without CAPOX as Perioperative Therapy for Resectable Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma NCT07802288 · ClinicalTrials.gov ↗ · Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma	Phase 2	Not yet open	Tianjin Medical University Cancer Institute and Hospital	China
Trastuzumab Combined With Retlirafusp Alfa in Treating HER2（Human Epidermal Growth Factor Receptor 2） 2+/3+ Gastric/Gastroesophageal Junction Adenocarcinoma After First-line Systemic Therapy Failure NCT07817654 · ClinicalTrials.gov ↗ · GC, GEJC	Phase 2	Not yet open	Henan Cancer Hospital	China
Trastuzumab Rezetecan Plus Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer NCT07843303 · ClinicalTrials.gov ↗ · Ovarian Cancer, Fallopian Tube Cancers, Primary Peritoneal Cancer	Phase 2	Not yet open	Peking University Cancer Hospital & Institute	China
SHR-A1811 Versus Trastuzumab Plus Pertuzumab in ctDNA-Positive HER2-Positive Early Breast Cancer After Pathologic Complete Response NCT07856303 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer, Early Breast Cancer (EBC)	Phase 2	Not yet open	Fudan University	China
Response-Guided Bladder Preservation With Trastuzumab Rezetecan, Adebrelimab, and Concurrent Bladder Radiotherapy in HER2-Expressing Muscle-Invasive Bladder Cancer NCT07865611 · ClinicalTrials.gov ↗ · Muscle-Invasive Bladder Cancer (MIBC)	Phase 2	Not yet open	Tongji Hospital	China
Neoadjuvant SHR-A1811 ± Adebrelimab in GC/GEJ NCT07912957 · ClinicalTrials.gov ↗ · Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma	Phase 2	Not yet open	Fudan University	China
SHR - A1811 Injection in the Treatment of Platinum-sensitive Recurrent Ovarian Cancer NCT06990516 · ClinicalTrials.gov ↗ · Ovarian Cancer	Phase 1/2	Not yet open	Tongji Hospital	China
A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane NCT05424835 · ClinicalTrials.gov ↗ · HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane	Phase 3	Active, closed	Jiangsu HengRui Medicine Co., Ltd	China
SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial NCT05814354 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 3	Active, closed	Jiangsu HengRui Medicine Co., Ltd	China
A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer NCT06057610 · ClinicalTrials.gov ↗ · HER2-PositiveRecurrent or Metastatic Breast Cancer	Phase 3	Active, closed	Jiangsu HengRui Medicine Co., Ltd	China
A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy NCT06126640 · ClinicalTrials.gov ↗ · HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy	Phase 3	Active, closed	Jiangsu HengRui Medicine Co., Ltd	China
Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan NCT06199973 · ClinicalTrials.gov ↗ · Advanced Colorectal Cancer	Phase 3	Active, closed	Suzhou Suncadia Biopharmaceuticals Co., Ltd	China
A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer NCT07196774 · ClinicalTrials.gov ↗ · Early-stage or Locally Advanced HER2-positive Breast Cancer	Phase 3	Active, closed	Jiangsu HengRui Medicine Co., Ltd	China
A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing NCT05924256 · ClinicalTrials.gov ↗ · Advanced Salivary Gland Carcinoma	Phase 2	Active, closed	Fudan University	China
Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer NCT06413745 · ClinicalTrials.gov ↗ · HER2 Expression / Amplification in Patients With Biliary Tract Cancer	Phase 2	Active, closed	Jiangsu HengRui Medicine Co., Ltd	China
Trastuzumab Rezetecan and Adebrelimab as Neoadjuvant Therapy for HER2-Positive Muscle-Invasive Bladder Cancer NCT07624201 · ClinicalTrials.gov ↗ · Muscle-Invasive Bladder Cancer (MIBC)	Phase 2	Active, closed	Harbin Medical University	China
A Real-World Study of Trastuzumab Rezetecan in HER2+ Solid Tumors NCT07387874 · ClinicalTrials.gov ↗ · Recurrent or Metastatic Solid Tumors	Observational	Active, closed	Lixiaoling	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Conditions studied with Trastuzumab Rezetecan

74 conditions

Breast Cancer8 Advanced Breast Cancer7 Ovarian Cancer6 HER2-positive Breast Cancer5 HER2-negative Breast Cancer3HER2 + Breast Cancer3Recurrent or Metastatic Cervical Cancer2Breast Neoplasm2HR Positive/HER2 Low Breast Cancer2Breast Cancer Early Stage Breast Cancer (Stage 1-3)2Non Small Cell Lung Cancer2 Metastatic Breast Cancer2

All 74 conditions

Condition (as registered)	Trials
Breast Cancer	8
Advanced Breast Cancer	7
Ovarian Cancer	6
HER2-positive Breast Cancer	5
HER2-negative Breast Cancer	3
HER2 + Breast Cancer	3
Recurrent or Metastatic Cervical Cancer	2
Breast Neoplasm	2
HR Positive/HER2 Low Breast Cancer	2
Breast Cancer Early Stage Breast Cancer (Stage 1-3)	2
Non Small Cell Lung Cancer	2
Metastatic Breast Cancer	2
Solid Tumor	2
Biliary Tract Neoplasms Immunotherapy	2
Muscle-Invasive Bladder Cancer (MIBC)	2
Advanced Colorectal Cancer	1
HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma	1
Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma	1
Advanced Gastric Cancer	1
Metastatic Gastric Cancer	1
Gastroesophageal Junction Adenocarcinoma	1
Early Breast Cancer (EBC)	1
HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy	1
PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer	1
HER2positive	1
Urachal Cancer	1
Advanced Solid Tumor Cancer	1
Antibody-drug Conjugates	1
Advanced Breast Cancer With Ultra-Low HER2 Expression	1
Breast Tumors	1
Triple-Negative Breast Cancer (TNBC)	1
Breast Cancer Metastatic	1
Breast Cancer Brain Metastases	1
Early-stage or Locally Advanced HER2-positive Breast Cancer	1
Pancreatic Cancer	1
Non-Small Cell Lung Cancer With HER2- Mutations	1
HER2-expressing Advanced Solid Tumors	1
HER2 Low Breast Carcinoma	1
HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane	1
Solid Tumors	1
HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer	1
Gastric Adenocarcinoma	1
Gastroesophageal Junction (GEJ) Adenocarcinoma	1
Serplulimab Combined With SHR-A1811 as Neoadjuvant Therapy for Triple-Negative Breast Cancer	1
HER2-PositiveRecurrent or Metastatic Breast Cancer	1
Gastric Cancer	1
Gastroesophageal-junction Cancer	1
Fallopian Tube Cancers	1
Primary Peritoneal Cancer	1
Advanced Salivary Gland Carcinoma	1
Triple Negative Breast Cancer (TNBC)	1
Hormone Receptor Positive Tumor	1
HER2 Expression / Amplification in Patients With Biliary Tract Cancer	1
Platinum Sensitive Ovarian Cancer (PSOC)	1
Triple-negative Breast Cancer	1
HER2-positive Early Breast Cancer	1
UTUC	1
Triple Negative Breast Cancer	1
Urothelial Carcinoma	1
Advanced Urothelial Carcinoma	1
Urothelial Carcinoma Recurrent	1
Recurrent or Metastatic Solid Tumors	1
Metastatic Breast Cancer (MBC)	1
HER2-Positive Breast Cancer	1
Hormone Receptor-Positive Breast Cancer	1
HER2-positive Advanced Breast Cancer	1
Brain Metastases	1
Radiotherapy	1
Unresectable Locally Recurrent Breast Cancer	1
Unresectable Locally Metastatic Breast Cancer	1
Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma	1
HER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis	1
GC	1
GEJC	1

By country register

Register	Trials	Recruiting
Clinical trials in China	75	42

A trial with sites in more than one country appears in each of those registers.

Related compounds

Questions about Trastuzumab Rezetecan trials

How many clinical trials are testing Trastuzumab Rezetecan?

75 current trials in our China register name Trastuzumab Rezetecan (also registered as SHR-A1811) as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.

Are Trastuzumab Rezetecan trials recruiting patients?

Yes. 42 of the 75 trials are recruiting: 42 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Trastuzumab Rezetecan clinical trials?

Jiangsu HengRui Medicine Co., Ltd (14), Fudan University (13), Suzhou Suncadia Biopharmaceuticals Co., Ltd (10) and Henan Cancer Hospital (5), among 26 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Trastuzumab Rezetecan works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Trastuzumab Rezetecan works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Trastuzumab Rezetecan (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.